Loading
Chemotherapy-related Skin Toxicity / Cancer Treatment and Pharmacology / Cancer Related Cognitive Impairment Studies · Review
Journal of Pain Research · September 1, 2026
Well-designed and adequately powered for the question it asks.
This systematic review and meta-analysis synthesizes evidence from 197 studies across 36 countries to estimate that chronic chemotherapy-induced peripheral neuropathy affects 44.50% (95% CI 40.77–48.25%) of cancer survivors. Prevalence varies substantially by time since chemotherapy completion, geographic region, chemotherapy type, and cancer type, suggesting that risk is not uniform across populations.
Systematic review and meta-analysis. Studies of patients who received neurotoxic chemotherapy and were assessed for chronic CIPN (defined as persisting ≥3 months after chemotherapy completion).. n = 72,794. 36 countries.
Global pooled prevalence of chronic CIPN: 44.50% (95% CI 40.77–48.25%) Prevalence at 3–12 months post-chemotherapy: 54.37% (95% CI 48.24–60.45%) Prevalence at 12–24 months post-chemotherapy: 37.12% (95% CI 30.15–44.26%)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that chronic CIPN affects nearly half of cancer survivors and persists long after chemotherapy completion. The substantial burden and demonstrated variation by population and regimen support implementation of targeted surveillance, prevention strategies, and symptom management protocols, particularly for high-risk groups.
Systematic review and meta-analysis of 197 studies with 72,794 patients providing a pooled prevalence estimate with confidence interval; rigorous methodology but epidemiological rather than intervention-based evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that chronic CIPN affects nearly half of cancer survivors and persists long after chemotherapy completion. The substantial burden and demonstrated variation by population and regimen support implementation of targeted surveillance, prevention strategies, and symptom management protocols, particularly for high-risk groups.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse effect of neurotoxic chemotherapy agents. Despite its substantial global burden, the prevalence of chronic CIPN (persisting for ≥ 3 months after completion of chemotherapy) remains uncertain. We aimed to estimate the global prevalence of chronic CIPN and assess variations based on chemotherapy regimen, cancer type, geographic region, and human development index (HDI). Methods: A systematic search of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus was conducted from database inception to May 2025. A random-effects model with Freeman-Tukey transformation was used for meta-analysis. The primary outcome was the global prevalence of chronic CIPN. Subgroup analysis explored prevalence by time since chemotherapy completion, geographic region, chemotherapy regimen, cancer type, and study design. Results: A total of 197 studies from 36 countries (72,794 patients who received chemotherapy, 26,258 with chronic CIPN) were included. The pooled global prevalence of chronic CIPN was 44.50% (95% CI 40.77– 48.25). Subgroup analyses revealed significant variation by geographic region, chemotherapy class, and cancer type. Chronic CIPN prevalence was 54.37% (95% CI 48.24– 60.45) at 3– 12 months post-chemotherapy, 37.12% (95% CI 30.15– 44.26) at 12– 24 months post-chemotherapy, and 40.36% (95% CI 34.72– 46.08) at ≥ 24 months post-chemotherapy. Conclusion: Chronic CIPN affects a substantial proportion of cancer survivors, with prevalence influenced by time since completion of chemotherapy, geographic region, chemotherapy type, and cancer type. These findings highlight the need for targeted surveillance, prevention, and management, particularly for high-risk populations. Keywords: chemotherapy-induced peripheral neuropathy, peripheral neuropathy, epidemiology, public health, prevalence, systematic review, meta-analysis
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.